Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements (2024 and earlier)

Company Profile

Business Address 950 TOWER LANE, SUITE 1050
FOSTER CITY, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments151,719156,541231,820116,660
Cash and cash equivalents28,00331,340142,08611,970
Short-term investments123,716125,20189,734104,690
Receivables23,9943,267  
Inventory, net of allowances, customer advances and progress billings5,5651,513  
Inventory5,5651,513  
Other undisclosed current assets8,9475,2714,5302,703
Total current assets:190,225166,592236,350119,363
Noncurrent Assets
Operating lease, right-of-use asset1,4311,5691,9492,361
Property, plant and equipment9149811,2931,372
Long-term investments and receivables  4,983 23,292
Long-term investments  4,983 23,292
Intangible assets, net (including goodwill)58,95418,740  
Intangible assets, net (excluding goodwill)58,95418,740  
Other noncurrent assets1,3821,7861,272324
Other undisclosed noncurrent assets 100,000100,000  
Total noncurrent assets:162,681128,0594,51427,349
TOTAL ASSETS:352,906294,651240,864146,712
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities62,70839,88916,56212,679
Accounts payable8,6909,1663,1513,351
Accrued liabilities54,01830,72313,4119,328
Debt    397
Derivative instruments and hedges, liabilities 1,0901,9961,264 
Other undisclosed current liabilities931711636 
Total current liabilities:64,72942,59618,46213,076
Noncurrent Liabilities
Long-term debt and lease obligation 1,9032,6273,251
Long-term debt, excluding current maturities    
Liabilities, other than long-term debt5,789172936
Other liabilities4,532172936
Operating lease, liability1,2571,9032,6273,251
Other undisclosed noncurrent liabilities 140,351129,92347,651 
Total noncurrent liabilities:146,140131,84350,3073,287
Total liabilities:210,869174,43968,76916,363
Equity
Equity, attributable to parent142,037120,212172,095130,349
Common stock4332
Additional paid in capital535,074377,403345,180200,119
Accumulated other comprehensive income (loss)(217)(35)83129
Accumulated deficit(392,824)(257,159)(173,171)(69,901)
Total equity:142,037120,212172,095130,349
TOTAL LIABILITIES AND EQUITY:352,906294,651240,864146,712

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues77,06219,138  
Gross profit:77,06219,138  
Operating expenses(208,282)(192,551)(104,296)(54,743)
Operating loss:(131,220)(173,413)(104,296)(54,743)
Nonoperating income (expense)4,222(216)1,3672,211
Investment income, nonoperating3,8573661,5592,232
Other nonoperating income (expense)365(582)(192)(21)
Interest and debt expense    
Loss from continuing operations before equity method investments, income taxes:(126,998)(173,629)(102,929)(52,532)
Other undisclosed income (loss) from continuing operations before income taxes(15,073)89,678(335) 
Loss from continuing operations before income taxes:(142,071)(83,951)(103,264)(52,532)
Income tax expense (benefit)6,406(37)(6)(21)
Loss from continuing operations:(135,665)(83,988)(103,270)(52,553)
Loss before gain (loss) on sale of properties:(83,988)(103,270)(52,553)
Net loss available to common stockholders, basic:(135,665)(83,988)(103,270)(52,553)
Other undisclosed net loss available to common stockholders, diluted(914)   
Net loss available to common stockholders, diluted:(136,579)(83,988)(103,270)(52,553)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(135,665)(83,988)(103,270)(52,553)
Comprehensive loss:(135,665)(83,988)(103,270)(52,553)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(182)(118)(46)129
Comprehensive loss, net of tax, attributable to parent:(135,847)(84,106)(103,316)(52,424)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: